Cat. No.: HY-116009

Copy Link Print Information

RMC-4550

11 Cited Publications

Customer Review

Based on 11 publication(s) in Google Scholar

RMC-4550 is a potent, selective and allosteric inhibitor of SHP2, with an IC₅₀ of 0.583 nM.

For research use only. We do not sell to patients.

Purity: 99.56%
CAS No.: 2172651-73-7
Formula: C₂₁H₂₆Cl₂N₄O₂
Molecular Weight:437.36

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

RMC-4550 Chemical Structure

CAS No.: 2172651-73-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (11)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

RMC-4550 is a potent, selective and allosteric inhibitor of SHP2, with an IC₅₀ of 0.583 nM.

IC₅₀ & Target

IC50:0.583 nM (SHP2)^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
KYSE-520 cell line	IC₅₀	4550 nM Compound: RMC-4550	Antiproliferative activity against human KYSE520 cells assessed as inhibition of cell proliferation incubated for 96 hrs by CellTiter-Glo reagent based assay Antiproliferative activity against human KYSE520 cells assessed as inhibition of cell proliferation incubated for 96 hrs by CellTiter-Glo reagent based assay	[PMID: 37197453]

In Vitro

RMC-4550 is an allosteric inhibitor of SHP2 and stabilizes the auto-inhibited conformation of wild-type SHP2 enzyme, with a mode of inhibition similar to SHP099. Consistent with an allosteric mode of inhibition, RMC-4550 inhibits the activity of full-length wild-type SHP2 enzyme activated by a di-phosphotyrosine peptide, but lacks activity against the free catalytic domain of SHP2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 2172651-73-7
Appearance Solid
Molecular Weight 437.36
Formula C₂₁H₂₆Cl₂N₄O₂
Color White to light yellow
SMILES

ClC1=C(C(C2=NC(CO)=C(N=C2C)N3CCC4(CC3)CO[C@H]([C@H]4N)C)=CC=C1)Cl
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (11)

All WBIn Vivo Efficacy StudyCell Proliferation/Viability AssayCell Imaging/Staining

Sort by:

Journal Impact Factor

Cancer Discov

Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. [Abstract]

2021 Jul;11(7):1716-1735. PMID: 33568355

RMC-4550 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2021 Jul;11(7):1716-1735. [Abstract]

RKO cells were treated for 2 hr with the SHP2 inhibitor RMC-4550 (2 μM, 2 h) to suppress endogenous RAS activity. Cell lysates were then either subjected to immunoprecipitation with a MEK antibody followed by immunoblotting for BRAF, or immunoblotted with the indicated antibodies.
Nat Cell Biol

RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. [Abstract]

2025 Dec 1. PMID: 41326795
Cancer Res

PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated Cancers. [Abstract]

2025 Sep 24. PMID: 40991405
Cancer Res

Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities. [Abstract]

2022 Apr 15;82(8):1589-1602. PMID: 35425962

RMC-4550 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2022 Apr 15;82(8):1589-1602. [Abstract]

Relative tumor burden after treatment with capivasertib, RMC-4550 (30 mg/kg, 5 days on, 2 days off, for 17 days), and combination of these drugs compared with tumor burden in vehicle-treated mice.

RMC-4550 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2022 Apr 15;82(8):1589-1602. [Abstract]

Drug dose-response matrix depicting percent growth inhibition of a murine Onc-negativeRAS/PI3K cell line after four days of treatment with the indicated doses of RMC-4550 (0-10 μM) and capivasertib. The average responses of three to four replicates are shown for each treatment.

RMC-4550 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2022 Apr 15;82(8):1589-1602. [Abstract]

Volumes of cell-line derived allografts from a murine Onc-negativeRAS/PI3K cell lines (MY-C3). 17 days after subcutaneous transplantation, 3 mice were treated with vehicle and 3 mice received RMC-4550 (30 mg/kg, 5 days on, 2 days off, for 30 days) and capivasertib.
Cancer Res

NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma. [Abstract]

2020 Aug 15;80(16):3413-3423. PMID: 32586982
Nat Commun

Mapping the landscape of genetic dependencies in chordoma. [Abstract]

2023 Apr 6;14(1):1933. PMID: 37024492

RMC-4550 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Apr 6;14(1):1933. [Abstract]

Colony formation assays of chordoma and non-chordoma (negative control A2058; positive control MDA-MB-468) cell lines treated with indicated concentrations of RMC-4550 (0-10 μM) for 14 days.

RMC-4550 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Apr 6;14(1):1933. [Abstract]

Immunoblot analysis of chordoma and non-chordoma (negative control A2058; positive control MDA-MB-468) cell lines treated with indicated concentrations of RMC-4550 (0.5 and 5 μM), SHP099, or DMSO for 2 h.
EMBO J

DNGR-1 signalling limits dendritic cell activation for optimal antigen cross-presentation. [Abstract]

2025 Oct 29. PMID: 41162754
Clin Transl Med

SHP2 inhibition and adjuvant therapy synergistically target KIT-mutant GISTs via ERK1/2-regulated GSK3β/cyclin D1 pathway. [Abstract]

2025 Feb;15(2):e70231. PMID: 39981588
Patent

US20250367204A1.
bioRxiv

Synergistic effects of deleting the tyrosine phosphatases Shp1 and Shp2 on megakaryopoiesis and thrombopoiesis in mice. [Abstract]

2025 Oct 26:2025.10.24.684367. PMID: 41279089
bioRxiv

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. [Abstract]

2025 Jun 7:2025.06.04.657911. PMID: 40502048

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (228.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2864 mL

11.4322 mL

22.8645 mL

5 mM

0.4573 mL

2.2864 mL

4.5729 mL

10 mM

0.2286 mL

1.1432 mL

2.2864 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (2.29 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (2.29 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (2.29 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Nichols RJ, et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 Sep;20(9):1064-1073. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2864 mL	11.4322 mL	22.8645 mL	57.1612 mL
	5 mM	0.4573 mL	2.2864 mL	4.5729 mL	11.4322 mL
	10 mM	0.2286 mL	1.1432 mL	2.2864 mL	5.7161 mL
	15 mM	0.1524 mL	0.7621 mL	1.5243 mL	3.8107 mL
	20 mM	0.1143 mL	0.5716 mL	1.1432 mL	2.8581 mL
	25 mM	0.0915 mL	0.4573 mL	0.9146 mL	2.2864 mL
	30 mM	0.0762 mL	0.3811 mL	0.7621 mL	1.9054 mL
	40 mM	0.0572 mL	0.2858 mL	0.5716 mL	1.4290 mL
	50 mM	0.0457 mL	0.2286 mL	0.4573 mL	1.1432 mL
	60 mM	0.0381 mL	0.1905 mL	0.3811 mL	0.9527 mL
	80 mM	0.0286 mL	0.1429 mL	0.2858 mL	0.7145 mL
	100 mM	0.0229 mL	0.1143 mL	0.2286 mL	0.5716 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

RMC-4550

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Phosphatase Inhibitor Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) RMC-4550

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

RMC-4550

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Phosphatase Inhibitor Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) RMC-4550

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

RMC-4550 Related Classifications

HY-116009 Related Classifications